Watch ANIX. Know when insiders buy.
One email the day a filing lands. Free.
ANIX
Anixa Biosciences Inc
2.78
+0.07 +2.58%
USD · Oct 23, 07:20 a.m. ET
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
67
PASS · insiders 87, shorts 46
Insiders, 90 days
+$252K
net buying · 8 buys, 0 sells · cluster
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $96.6MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$10.4MNET CASH $1M52W 2.35 – 5.22SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q3 2026 · Jul 31 | — | — | — | −$2.7M | −$2.6M | — | -0.08 | −$1.8M | — | — | Sep 9 |
| Q2 2026 · Apr 30 | — | — | — | −$2.6M | −$2.5M | — | -0.07 | −$1.7M | — | — | Jun 10 |
| Q1 2026 · Jan 31 | — | — | — | −$2.7M | −$2.6M | — | -0.08 | −$2.6M | — | — | Mar 9 |
| Q4 2025 · Oct 31derived | — | — | — | −$2.9M | −$2.7M | — | -0.09 | −$1.3M | — | — | Jan 12 |
| Q3 2025 · Jul 31 | — | — | — | −$2.4M | −$2.3M | — | -0.07 | −$1.5M | — | — | Sep 9 |
| Q2 2025 · Apr 30 | — | — | — | −$3M | −$2.8M | — | -0.09 | −$1.5M | — | — | Jun 10 |
| Q1 2025 · Jan 31 | — | — | — | −$3.4M | −$3.2M | — | -0.10 | −$2.9M | — | — | Mar 9 |
| Q4 2024 · Oct 31derived | — | — | — | −$3.2M | −$2.9M | — | -0.09 | −$927K | — | — | Jan 12 |
| Q3 2024 · Jul 31 | — | — | — | −$3.6M | −$3.3M | — | -0.10 | −$2.6M | — | — | Sep 10 |
| Q2 2024 · Apr 30 | — | — | — | −$3.5M | −$3.1M | — | -0.10 | −$1.5M | — | — | May 28 |
| Q1 2024 · Jan 31 | — | — | — | −$3.6M | −$3.3M | — | -0.10 | −$2.3M | — | — | Mar 11 |
| Q4 2023 · Oct 31derived | $0 | — | — | −$3.1M | −$2.7M | — | -0.09 | −$2M | — | — | Jan 10 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Oct 31 | — | — | −$11.7M | −$10.9M | — | -0.34 | −$7.2M | — | — | — | — |
| FY2024 · to Oct 31 | $210K | — | −$13.8M | −$12.6M | -5978.1% | -0.39 | −$7.3M | — | — | $6K | — |
| FY2023 · to Oct 31 | $210K | — | −$11M | −$9.8M | -4671.9% | -0.32 | −$6.2M | — | — | — | — |
| FY2022 · to Oct 31 | — | — | −$13.9M | −$13.6M | — | 0.45 | −$6.5M | — | — | — | — |
| FY2021 · to Oct 31 | $512K | — | −$13.1M | −$13M | -2530.1% | -0.45 | −$4.9M | — | — | — | — |
| FY2020 · to Oct 31 | — | — | −$10M | −$10M | — | -0.45 | −$6.2M | $16K | −$6.2M | — | — |
Every number comes from Anixa Biosciences Inc's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.